JP Morgan has maintained its underweight rating on pharmaceutical company GSK with a price target of £17 for June 2027. The bank sees limited potential for near-term earnings upgrades and remains cautious about GSK's long-term outlook, which depends heavily on successful drug pipeline developments and new product launches. JP Morgan's sales forecasts for 2031 are about 8% below market consensus, reflecting skepticism about contributions from new drugs like Exdensur and Blenrep. Key upcoming events to watch include Phase III trial data for a hepatitis B treatment in late May and trial results for camlipixant in July, along with GSK's Q2 results and pipeline update in late July.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
